VECTIBIX

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, Poland, Romania, Singapore, South Africa, Spain, Turkey, UK.

Active ingredients

The drug VECTIBIX contains one active pharmaceutical ingredient (API):

1	Panitumumab UNII 6A901E312A - PANITUMUMAB
	Panitumumab is a recombinant, fully human IgG2 monoclonal antibody that binds with high affinity and specificity to the human EGFR. Panitumumab binds to the ligand binding domain of EGFR and inhibits receptor autophosphorylation induced by all known EGFR ligands. Binding of panitumumab to EGFR results in internalisation of the receptor, inhibition of cell growth, induction of apoptosis, and decreased interleukin 8 and vascular endothelial growth factor production.
	Read more about Panitumumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VECTIBIX Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FE02	Panitumumab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FE EGFR (Epidermal Growth Factor Receptor) inhibitors
Discover more medicines within L01FE02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10069Y, 10082P, 10508C, 10513H
BR	Câmara de Regulação do Mercado de Medicamentos	544115070000317, 544115070000417
CA	Health Products and Food Branch	02308487, 02308509
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	H6200713
EE	Ravimiamet	1342279, 1342280, 1342291
ES	Centro de información online de medicamentos de la AEMPS	07423001, 07423003
FI	Lääkealan turvallisuus- ja kehittämiskeskus	119031, 119053
FR	Base de données publique des médicaments	66403621
GB	Medicines & Healthcare Products Regulatory Agency	130945, 146891
HK	Department of Health Drug Office	61371
IL	מִשְׂרַד הַבְּרִיאוּת	6331
IT	Agenzia del Farmaco	038347011, 038347035
JP	医薬品医療機器総合機構	4291417A1020, 4291417A2027
LT	Valstybinė vaistų kontrolės tarnyba	1031148, 1031150
NL	Z-Index G-Standaard, PRK	85812, 87459
PL	Rejestru Produktów Leczniczych	100027929
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W52724001, W52724003
SG	Health Sciences Authority	14498P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699862760010, 8699862760027
US	FDA, National Drug Code	55513-954, 55513-956
ZA	Health Products Regulatory Authority	44/30.1/0110, 44/30.1/0111, 44/30.1/0112